Every election, we hear the same old song: a bold promise to finally “take on Big Pharma.” This time, it’s Donald Trump in the spotlight, claiming he’s brokered a deal to bring down drug prices. And sure, a few prices might dip for a little while. But let’s not mistake a few targeted discounts for…
The whole point of the Affordable Care Act (ACA) was to make health insurance something regular people could actually get and afford. A considerable part of that has been the extra help with monthly premiums that started with the American Rescue Plan and was later extended. These subsidies have been a lifeline, helping millions of…
Claims that Donald Trump reduced drug prices by “600%” are mathematically impossible and unsupported by real-world outcomes. Likewise, blaming Democrats for rising healthcare costs ignores the structural issues that have driven inflation for decades. High healthcare and drug prices are the result of systemic incentives, consolidation, and profit-driven design—not a single political party or presidency….
Physicians are most receptive when content is concise, evidence-first, tied to guidelines or real-world outcomes, and delivered through trusted channels (society journals/conferences, point-of-care tools, KOLs/MSLs, or EHR/Care Pathway integrations), but pharma HCP sites try too hard to “sell” rather than provide the information they need to treat patients. Something wasn’t right. My client spent a…
The core problem in U.S. healthcare is not who pays the bills, but how large the bills have become. Shifting more costs to insurance companies only leads to higher premiums and reduced coverage. Shifting more costs to the government ultimately means higher taxes or public debt. Without addressing the underlying drivers of healthcare spending—overutilization, misaligned…
Calls to put a black box warning on COVID-19 vaccines may sound like “playing it safe,” but they would likely do the opposite—undermining public health, confusing patients, and eroding trust without improving safety. Black box warnings are meant for drugs with clear, frequent, and severe risks. Applying that label to vaccines with a strong benefit–risk…
Americans live in a paradox when it comes to prescription drugs. On one hand, patients know they need medications to stay healthy, manage chronic conditions, or simply function day-to-day. On the other hand, they resent — often deeply — the very industry that produces those lifesaving therapies. It’s a need-hate relationship, and it’s getting worse. Pharma’s strategy…
A new citizen petition filed with the U.S. Food and Drug Administration (FDA) by Children’s Health Defense (CHD) — an organization founded by Health and Human Services Secretary Robert F. Kennedy Jr. — is grabbing headlines this week. The petition requests that the FDA revoke the full licenses for the Pfizer-BioNTech and Moderna COVID-19 vaccines, arguing that regulatory procedures…
The WHO’s recent comments that GLP-1 medications won’t meaningfully reduce global obesity rates should be a wake-up call for every stakeholder—clinicians, policymakers, employers, and yes, pharma. The reality is simple: obesity is not a “drug problem.” It’s a systems problem. And while GLP-1s like Ozempic and Wegovy have produced remarkable clinical outcomes, they were never going to…
Every few years, political talking points resurface claiming that the Affordable Care Act (ACA), commonly known as Obamacare, is riddled with fraud and waste. It’s an easy narrative because “government program” and “fraud” tend to get paired together in headlines. But when you look at the data, the reality is clear: fraud tied directly to ACA…